New hope for advanced breast cancer: HRS-8080 takes on hormone-resistant tumors
NCT ID NCT07024173
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called HRS-8080 against standard treatments chosen by doctors for women with advanced breast cancer that has worsened after hormone therapy. About 240 women aged 18-75 will take part. The main goal is to see if HRS-8080 can delay cancer growth longer than current options.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hunan Cancer Hospital
RECRUITINGChangsha, Hunan, 410000, China
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Drug attack shrink Hard-to-Treat breast cancer?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Could a personal coach at home boost energy for cancer patients?
- Can an immune booster help chemotherapy fight metastatic breast cancer?
- Can a Four-Drug cocktail tame a tough breast cancer?
- Can a new drug outsmart resistant breast cancer?